peptide labs semaglutide Buy NZ Semaglutide

Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations

The latest data shows that 1 in 8 Americans have used a GLP-1, with ~15 million currently using them

If nausea, vomiting, or gastrointestinal distress becomes severe, slowing your dose escalation or extending time at your current dose allows better adaptation

Currently 18% of the U.S